The combined company starts life with Crestovo’s phase 2 Clostridium difficile candidate and a large-scale stool donation program.
DBV Technologies’ peanut allergy vaccine missed the mark in a phase 3 trial but is still at least 50:50 for FDA approval, say analysts at Jefferies.
South Korean, Celltrion group is a global leader for biologic medicine and is a pioneer in the approval of biosimilar profile in Europe, US and Brazil. The…
MIT scientists have devised a gene circuit that could identify cancer cells more accurately and stimulate the immune system more effectively.
A team of scientists led by the University of Buffalo has developed a vaccine that may guard against 72 strains of the bacterium that causes pneumonia.
Brought to you by the publisher of FierceBiotech and FiercePharma, the Fierce Innovation Awards Life Sciences Edition identify and showcase outstanding…
Celgene has scrapped a phase 3 trial of inflammatory bowel disease drug GED-0301 after it failed to clear an interim futility review.
The deal gives Roivant, Axovant’s parent company, another part-developed, unloved drug to try to turn into a star.
Gilead boosted oncology chief Riva to EVP, Moderna lost three top R&D officials, Bayer poached Pfizer's consumer marketing vet and more.
Mebias presented rat data showing its mu opioid drugs could become a weapon in the scramble to combat the opioid epidemic.
Johnson & Johnson has notched a deal with Arcturus Therapeutics to help with its new focus on hepatitis B.
Scientists at Max Planck Florida have developed a tool that allows for precise genome editing of neurons.